The trend of incidence and burden of neurological disease in Iran between 1990 and 2017: Based on global burden of disease estimations

  • Hedayat Abbastabar Advanced Diagnostic and Interventional Radiology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Sama Bitarafan Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  • Mohammad Hossein Harirchian Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Keywords: Incidence, Global Burden of Disease, Disability-Adjusted Life Year, Neurological Disorders, Iran

Abstract

Neurological disease contributes significantly to morbidity and mortality in different ages and geographic areas around the world. The purpose of the current study was to investigate the incidence and disability-adjusted life years (DALYs) trend of neurological disease in Iran during 27 years ago. We used the data of the Global Burden of Disease (GBD) Study to estimate the incidence and DALYs of neurological disease in Iran in different age groups between 1990 and 2017. Age groups were defined in 5 groups including < 5 years, 5-14 years, 15-49 years, 50-69 years, and ≥ 70 years. The incidence number of neurological disease during 1990 to 2017 increased from 7.5 million to more than 12 million and the incidence rate grew as much as 1400 per 100000 populations in Iran. Totally, headache, epilepsy, and Alzheimer were the most common neurological diseases according to incidence and had the most values of DALY in Iran. The highest incidence and DALY of neurological disease was observed in the age group of 15-49 years. This study showed that the incidence and burden of neurological diseases had a dramatic increasing trend during 27 years ago in Iran. Consequently, it is necessary to investigate the causes of the growing trend in future studies.

References

1. Janca A, Prilipko L, Costa e Silva JA. The World Health Organization's work on public health aspects of neurology. J Neurol Neurosurg Psychiatry 1997; 63(Suppl 1): S6-S7.
2. Janca A, Prilipko L, Saraceno B. A World Health Organization perspective on neurology and neuroscience. Arch Neurol 2000; 57(12): 1786-8.
3. Kurtzke JF. Neuroepidemiology. Ann Neurol 1984; 16(3): 265-77.
4. Alwan AD, Galea G, Stuckler D. Development at risk: Addressing noncommunicable diseases at the United Nations high-level meeting. Bull World Health Organ 2011; 89(8): 546-546A.
5. World Health Organization. Causes of death in 2008. Geneva, Switzerland: WHO; 2011.
6. Cockerell OC, Sander JW, Shorvon SD. Neuroepidemiology in the United Kingdom. J Neurol Neurosurg Psychiatry 1993; 56(7): 735-8.
7. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19(1): 155-62.
8. World Bank. The growing danger of non-communicable diseases: Acting now to reverse course. Washington, DC: World Bank; 2011.
9. Murray CJL, Lopez AD, World Health Organization, World Bank, Harvard School of Public Health. The Global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary. Geneva, Switzerland: World Health Organization;1996
10. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053): 1603-58.
11. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 1994; 72(3): 495-509.
12. World Health Organization. Neurological disorders: Public health challenges. Geneva, Switzerland: WHO; 2006.
13. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1789-858.
14. Flaxman AD, Vos T, Murray CJL. An integrative metaregression framework for descriptive epidemiology. Seattle, WA: University of Washington Press; 2015.
15. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017; 16(11): 877-97.
16. Borlongan CV, Burns J, Tajiri N, Stahl CE, Weinbren NL, Shojo H, et al. Epidemiological survey-based formulae to approximate incidence and prevalence of neurological disorders in the United States: A meta-analysis. PLoS One 2013; 8(10): e78490.
17. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: A summary report and call to action. Ann Neurol 2017; 81(4): 479-84.
18. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007; 68(5): 326-37.
19. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6): 525-35.
20. Moosazadeh M, Esmaeili R, Mehdi NM, Abedi G, Afshari M, Farshidi F, et al. Prevalence of familial multiple sclerosis in Iran: A systematic review and meta-analysis. Iran J Neurol 2017; 16(2): 90-5.
21. Togha M, Shirbache K, Rahmanzadeh R, Ghorbani Z, Yari Z, Refaeian F, et al. Prevalence of new-onset migraine in patients with idiopathic intracranial hypertension in comparison to the general population. Iran J Neurol 2018; 17(4): 161-6.
22. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009; 49(4): 498-508.
23. Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: A review of statistics from national surveillance studies. Headache 2013; 53(3): 427-36.
24. Alzheimer’s Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement 2015; 11(3): 332-84.
25. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012; 8(2): 131-68.
26. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009; 85(1): 31-45.
27. Faught E, Richman J, Martin R, Funkhouser E, Foushee R, Kratt P, et al. Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries. Neurology 2012; 78(7): 448-53.
28. Chin JH, Vora N. The global burden of neurologic diseases. Neurology 2014; 83(4): 349-51.
29. Das SK, Biswas A, Roy J, Bose P, Roy T, Banerjee TK, et al. Prevalence of major neurological disorders among geriatric population in the metropolitan city of Kolkata. J Assoc Physicians India 2008; 56: 175-81.
30. Pringsheim T, Fiest K, Jette N. The international incidence and prevalence of neurologic conditions: how common are they? Neurology 2014; 83(18): 1661-4.
31. Kowalska M, Owecki M, Prendecki M, Wize K, Nowakowska J, Kozubski W, et al. Aging and Neurological Diseases, Senescence - Physiology or Pathology. In: Dorszewska J, Kozubski W, editors. London, UK: IntechOpen; 2017.
Published
2019-07-04
How to Cite
1.
Abbastabar H, Bitarafan S, Harirchian MH. The trend of incidence and burden of neurological disease in Iran between 1990 and 2017: Based on global burden of disease estimations. Iran J Neurol. 18(3):134-142.
Section
Review Article(s)